Kidney cancer patients may get a second chance with higher drug dose
NCT ID NCT05931393
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests whether a higher dose of the drug cabozantinib can help people with advanced kidney cancer whose cancer kept growing on the standard dose. About 18 adults whose cancer had been controlled by cabozantinib for at least 6 months before progressing will receive a higher dose. The goal is to see if the higher dose can shrink tumors or slow the cancer again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Conditions
Explore the condition pages connected to this study.